Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment

Pharmacology and Therapeutics

Volumn 132, Issue 3, 2011, Pages 314-332

  Pittenger, Christopher ^a,b   Bloch, Michael H ^a,b   Williams, Kyle ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Glutamate; Obsessive compulsive disorder; OCD

Indexed keywords

ACETYLCYSTEINE; EXCITATORY AMINO ACID TRANSPORTER 3; GLUTAMIC ACID; GLUTAMINE; GLYCINE; KETAMINE; LAMOTRIGINE; MEMANTINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PHENCYCLIDINE; RILUZOLE; SARCOSINE; TOPIRAMATE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTERIOR CINGULATE; ARTICLE; BINDING AFFINITY; BIPOLAR DEPRESSION; CEREBROSPINAL FLUID; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GLIA CELL; GROOMING; HUMAN; HYPERACTIVITY; LIVER INJURY; LIVER TOXICITY; NAUSEA; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSESSIVE COMPULSIVE DISORDER; PANCREATITIS; POSTSYNAPTIC DENSITY; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOTHERAPY; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TRICHOTILLOMANIA;

EID: 80054967901     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.09.006     Document Type: Review

References (223)

1. J.F. Abelson, K.Y. Kwan, B.J. O'Roak, D.Y. Baek, A.A. Stillman, and T.M. Morgan Sequence variants in SLITRK1 are associated with Tourette's syndrome Science 310 5746 2005 317 320 (Pubitemid 41457198)
2. E. Aboujaoude, J.J. Barry, and N. Gamel Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial J Clin Psychopharmacol 29 1 2009 51 55
3. N. Albelda, N. Bar-On, and D. Joel The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder Psychopharmacology (Berl) 210 1 2010 13 24
4. American Psychiatric Association Diagnostic and statistical manual of mental disorders 4th ed., text rev. 2000 10.1176/appi.books.9780890423349
5. S.L. Andersen, E.A. Greene-Colozzi, and K.C. Sonntag A novel, multiple symptom model of obsessive-compulsive-like behaviors in animals Biol Psychiatry 68 8 2010 741 747
6. G.M. Anderson, E.S. Pollak, D. Chatterjee, J.F. Leckman, M.A. Riddle, and D.J. Cohen Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome Adv Neurol 58 1992 123 133
7. K. Aoyama, S.W. Suh, A.M. Hamby, J. Liu, W.Y. Chan, and Y. Chen Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse Nat Neurosci 9 1 2006 119 126 (Pubitemid 43011917)
8. P.D. Arnold, F.P. Macmaster, M.A. Richter, G.L. Hanna, T. Sicard, and E. Burroughs Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder Psychiatry Res 172 2 2009 136 139
9. P.D. Arnold, D.R. Rosenberg, E. Mundo, S. Tharmalingam, J.L. Kennedy, and M.A. Richter Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study Psychopharmacology (Berl) 174 4 2004 530 538 (Pubitemid 39119342)
10. P.D. Arnold, T. Sicard, E. Burroughs, M.A. Richter, and J.L. Kennedy Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder Arch Gen Psychiatry 63 7 2006 769 776
11. M. Atmaca, H. Yildirim, H. Ozdemir, M. Koc, S. Ozler, and E. Tezcan Neurochemistry of the hippocampus in patients with obsessive-compulsive disorder Psychiatry Clin Neurosci 63 4 2009 486 490
12. D.P. Auer, B. Putz, E. Kraft, B. Lipinski, J. Schill, and F. Holsboer Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study Biol Psychiatry 47 4 2000 305 313 (Pubitemid 30109243)
13. M. Banasr, G.M. Chowdhury, R. Terwilliger, S.S. Newton, R.S. Duman, and K.L. Behar Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole Mol Psychiatry 15 5 2010 501 511
14. R. Bartha, M.B. Stein, P.C. Williamson, D.J. Drost, R.W. Neufeld, and T.J. Carr A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects Am J Psychiatry 155 11 1998 1584 1591 (Pubitemid 28512029)
15. M.J. Bedard, and S. Chantal Brain magnetic resonance spectroscopy in obsessive-compulsive disorder: the importance of considering subclinical symptoms of anxiety and depression Psychiatry Res 192 1 2011 45 54
16. N.R. Benazon, G.J. Moore, and D.R. Rosenberg Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy J Am Acad Child Adolesc Psychiatry 42 11 2003 1279 1285 (Pubitemid 39585987)
17. D.E. Bergles, and C.E. Jahr Glial contribution to glutamate uptake at Schaffer collateral-commissural synapses in the hippocampus J Neurosci 18 19 1998 7709 7716 (Pubitemid 28441012)
18. M. Berk, D.L. Copolov, O. Dean, K. Lu, S. Jeavons, and I. Schapkaitz N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial Biol Psychiatry 64 6 2008 468 475
19. H.A. Berlin, L.M. Koran, M.A. Jenike, N.A. Shapira, W. Chaplin, and S. Pallanti Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder J Clin Psychiatry 72 2011 716 721
20. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, and D.S. Charney Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 4 2000 351 354 (Pubitemid 30109248)
21. A.Y. Bespalov, M.M. van Gaalen, I.A. Sukhotina, K. Wicke, M. Mezler, and H. Schoemaker Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression Eur J Pharmacol 592 1-3 2008 96 102
22. S. Bhattacharyya, S. Khanna, K. Chakrabarty, A. Mahadevan, R. Christopher, and S.K. Shankar Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder Neuropsychopharmacology 34 12 2009 2489 2496
23. O.J. Bienvenu, Y. Wang, Y.Y. Shugart, J.M. Welch, M.A. Grados, and A.J. Fyer Sapap3 and pathological grooming in humans: results from the OCD collaborative genetics study Am J Med Genet B Neuropsychiatr Genet 150B 5 2009 710 720
24. M.H. Bloch, B.G. Craiglow, A. Landeros-Weisenberger, P.A. Dombrowski, K.E. Panza, and B.S. Peterson Predictors of early adult outcomes in pediatric-onset obsessive-compulsive disorder Pediatrics 124 4 2009 1085 1093
25. M.H. Bloch, A. Landeros-Weisenberger, B. Kelmendi, V. Coric, M.B. Bracken, and J.F. Leckman A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder Mol Psychiatry 11 7 2006 622 632 (Pubitemid 43989810)
26. M.H. Bloch, A. Landeros-Weisenberger, M.C. Rosario, C. Pittenger, and J.F. Leckman Meta-analysis of the symptom structure of obsessive-compulsive disorder Am J Psychiatry 165 12 2008 1532 1542
27. M.H. Bloch, A. Landeros-Weisenberger, S. Sen, P. Dombrowski, B. Kelmendi, and V. Coric Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review Am J Med Genet B Neuropsychiatr Genet 147B 6 2008 850 858
28. M.H. Bloch, J. McGuire, A. Landeros-Weisenberger, J.F. Leckman, and C. Pittenger Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder Mol Psychiatry 15 2010 850 855
29. M.H. Bloch, and C. Pittenger The genetics of obsessive-compulsive disorder Curr Psychiatry Rev 6 2010 91 103
30. L. Boardman, L. van der Merwe, C. Lochner, C.J. Kinnear, S. Seedat, and D.J. Stein Investigating SAPAP3 variants in the etiology of obsessive-compulsive disorder and trichotillomania in the South African white population Compr Psychiatry 52 2 2011 181 187
31. J. Bolton, G.J. Moore, S. MacMillan, C.M. Stewart, and D.R. Rosenberg Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD J Am Acad Child Adolesc Psychiatry 40 8 2001 903 906 (Pubitemid 32667072)
32. A.L. Brody, S. Saxena, J.M. Schwartz, P.W. Stoessel, K. Maidment, and M.E. Phelps FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder Psychiatry Res 84 1 1998 1 6 (Pubitemid 28546878)
33. K.M. Campbell, L. de Lecea, D.M. Severynse, M.G. Caron, M.J. McGrath, and S.B. Sparber OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons J Neurosci 19 12 1999 5044 5053 (Pubitemid 29270139)
34. K.M. Campbell, M.B. Veldman, M.J. McGrath, and F.H. Burton TS+OCD-like neuropotentiated mice are supersensitive to seizure induction Neuroreport 11 10 2000 2335 2338 (Pubitemid 30485587)
35. M.L. Carlsson On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions Acta Psychiatr Scand 102 6 2000 401 413
36. M.L. Carlsson On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder Prog Neuropsychopharmacol Biol Psychiatry 25 1 2001 5 26 (Pubitemid 32173787)
37. C.N. Carmin, P.S. Wiegartz, U. Yunus, and K.L. Gillock Treatment of late-onset OCD following basal ganglia infarct Depress Anxiety 15 2 2002 87 90 (Pubitemid 34252251)
38. I. Cavus, W.S. Kasoff, M.P. Cassaday, R. Jacob, R. Gueorguieva, and R.S. Sherwin Extracellular metabolites in the cortex and hippocampus of epileptic patients Ann Neurol 57 2 2005 226 235 (Pubitemid 40179861)
39. K. Chakrabarty, S. Bhattacharyya, R. Christopher, and S. Khanna Glutamatergic dysfunction in OCD Neuropsychopharmacology 30 9 2005 1735 1740 (Pubitemid 43086030)
40. D.C. Choi, B.O. Rothbaum, M. Gerardi, and K.J. Ressler Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder Curr Top Behav Neurosci 2 2010 279 299
41. W.L. Cleveland, R.L. DeLaPaz, R.A. Fawwaz, and R.S. Challop High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period Neural Plast 2009 2009 768398
42. S. Collins, M.J. Sigtermans, A. Dahan, W.W. Zuurmond, and R.S. Perez NMDA receptor antagonists for the treatment of neuropathic pain Pain Med 11 11 2010 1726 1742
43. V. Coric, B. Kelmendi, C. Pittenger, S. Wasylink, M.H. Bloch, and J. Green Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania J Clin Psychiatry 68 1 2007 170 171 (Pubitemid 46220144)
44. V. Coric, S. Milanovic, S. Wasylink, P. Patel, R. Malison, and J.H. Krystal Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder Psychopharmacology (Berl) 167 2 2003 219 220 (Pubitemid 36628165)
45. V. Coric, S. Taskiran, C. Pittenger, S. Wasylink, D.H. Mathalon, and G. Valentine Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial Biol Psychiatry 58 5 2005 424 428 (Pubitemid 41219711)
46. N.C. Danbolt Glutamate uptake Prog Neurobiol 65 1 2001 1 105 (Pubitemid 32479155)
47. R.M. Deacon Digging and marble burying in mice: simple methods for in vivo identification of biological impacts Nat Protoc 1 1 2006 122 124
48. O. Dean, F. Giorlando, and M. Berk N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action J Psychiatry Neurosci 36 2 2011 78 86
49. R. Delorme, C. Betancur, J. Callebert, N. Chabane, J.L. Laplanche, and M.C. Mouren-Simeoni Platelet serotonergic markers as endophenotypes for obsessive-compulsive disorder Neuropsychopharmacology 30 8 2005 1539 1547 (Pubitemid 41153126)
50. R. Delorme, M.O. Krebs, N. Chabane, I. Roy, B. Millet, and M.C. Mouren-Simeoni Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder Neuroreport 15 4 2004 699 702 (Pubitemid 38457164)
51. D.E. Dickel, J. Veenstra-VanderWeele, N.J. Cox, X. Wu, D.J. Fischer, and M. Van Etten-Lee Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder Arch Gen Psychiatry 63 7 2006 778 785
52. D.E. Dietrich, Y. Zhang, L. Bode, T.F. Munte, U. Hauser, and P. Schmorl Brain potential amplitude varies as a function of Borna disease virus-specific immune complexes in obsessive-compulsive disorder Mol Psychiatry 10 6 2005 519 520 515 (Pubitemid 40897033)
53. D. Ebert, O. Speck, A. Konig, M. Berger, J. Hennig, and F. Hohagen 1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum Psychiatry Res 74 3 1997 173 176 (Pubitemid 27315867)
54. N. Egashira, R. Okuno, S. Harada, M. Matsushita, K. Mishima, and K. Iwasaki Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder Eur J Pharmacol 586 1-3 2008 164 170
55. D. Eilam, R. Zor, H. Szechtman, and H. Hermesh Rituals, stereotypy and compulsive behavior in animals and humans Neurosci Biobehav Rev 30 4 2006 456 471
56. J. Epelbaum Sequence variants in SLITRK1 and Tourette's syndrome Med Sci (Paris) 21 12 2005 1117
57. C.N. Epperson, S. O'Malley, K.A. Czarkowski, R. Gueorguieva, P. Jatlow, and G. Sanacora Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy Biol Psychiatry 57 1 2005 44 48 (Pubitemid 39647590)
58. J.D. Feusner, L. Kerwin, S. Saxena, and A. Bystritsky Differential efficacy of memantine for obsessive-compulsive disorder vs generalized anxiety disorder: an open-label trial Psychopharmacol Bull 42 1 2009 81 93
59. M.E. Frizzo, L.P. Dall'Onder, K.B. Dalcin, and D.O. Souza Riluzole enhances glutamate uptake in rat astrocyte cultures Cell Mol Neurobiol 24 1 2004 123 128 (Pubitemid 38233735)
60. E. Fumagalli, M. Funicello, T. Rauen, M. Gobbi, and T. Mennini Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1 Eur J Pharmacol 578 2-3 2008 171 176 (Pubitemid 350309596)
61. K.A. Ganasen, J.C. Ipser, and D.J. Stein Augmentation of cognitive behavioral therapy with pharmacotherapy Psychiatr Clin North Am 33 3 2010 687 699
62. D. Geller, J. Biederman, J. Jones, K. Park, S. Schwartz, and S. Shapiro Is juvenile obsessive-compulsive disorder a developmental subtype of the disorder? A review of the pediatric literature J Am Acad Child Adolesc Psychiatry 37 4 1998 420 427 (Pubitemid 28162896)
63. D.C. Goff, C. Cather, J.D. Gottlieb, A.E. Evins, J. Walsh, and L. Raeke Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study Schizophr Res 106 2-3 2008 320 327
64. H.J. Grabe, S. Ruhrmann, S. Ettelt, F. Buhtz, A. Hochrein, and S. Schulze-Rauschenbach Familiality of obsessive-compulsive disorder in nonclinical and clinical subjects Am J Psychiatry 163 11 2006 1986 1992 (Pubitemid 44807791)
65. J.E. Grant, S.W. Kim, and B.L. Odlaug N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study Biol Psychiatry 62 6 2007 652 657 (Pubitemid 47314380)
66. P. Grant, L. Lougee, M. Hirschtritt, and S.E. Swedo An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder J Child Adolesc Psychopharmacol 17 2007 761 767 (Pubitemid 351158597)
67. J.E. Grant, B.L. Odlaug, S.R. Chamberlain, and S.W. Kim A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response J Clin Psychopharmacol 30 4 2010 396 403
68. J.E. Grant, B.L. Odlaug, and S.W. Kim N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study Arch Gen Psychiatry 66 7 2009 756 763
69. P. Grant, J.Y. Song, and S.E. Swedo Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder J Child Adolesc Psychopharmacol 20 4 2010 309 315
70. B.D. Greenberg, S.L. Rauch, and S.N. Haber Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD Neuropsychopharmacology 35 1 2010 317 336
71. W.M. Greenberg, M.M. Benedict, J. Doerfer, M. Perrin, L. Panek, and W.L. Cleveland Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults J Psychiatr Res 43 6 2009 664 670
72. J.M. Greer, and M.R. Capecchi Hoxb8 is required for normal grooming behavior in mice Neuron 33 1 2002 23 34 (Pubitemid 34088176)
73. R. Gross-Isseroff, R. Cohen, Y. Sasson, H. Voet, and J. Zohar Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan Neuropsychobiology 50 3 2004 200 205 (Pubitemid 39279410)
74. G.L. Hanna, J. Veenstra-VanderWeele, N.J. Cox, M. Boehnke, J.A. Himle, and G.C. Curtis Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands Am J Med Genet 114 5 2002 541 552 (Pubitemid 34680583)
75. E.S. Hansen, S. Hasselbalch, I. Law, and T.G. Bolwig The caudate nucleus in obsessive-compulsive disorder reduced metabolism following treatment with paroxetine: a PET study Int J Neuropsychopharmacol 5 1 2002 1 10 (Pubitemid 34241061)
76. G.E. Hardingham, and H. Bading Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders Nat Rev Neurosci 11 10 2010 682 696
77. K. Hashimoto Glycine transporter-1: a new potential therapeutic target for schizophrenia Curr Pharm Des 17 2 2011 112 120
78. D.M. Hezel, K. Beattie, and S.E. Stewart Memantine as an augmenting agent for severe pediatric OCD Am J Psychiatry 166 2 2009 237
79. C. Holden, and J. Travis Profile: Nicholas Dodman. Can dogs behaving badly suggest a new way to treat OCD? Science 329 5990 2011 386 387
80. E. Hollander, and B. Dell'Osso Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder Int Clin Psychopharmacol 21 3 2006 189 191 (Pubitemid 43740312)
81. E. Inouye Similar and dissimilar manifestations of obsessive-compulsive neuroses in monozygotic twins Am J Psychiatry 121 1965 1171 1175
82. D.E. Jane, D. Lodge, and G.L. Collingridge Kainate receptors: pharmacology, function and therapeutic potential Neuropharmacology 56 1 2009 90 113
83. M.A. Jenike Clinical practice. Obsessive-compulsive disorder N Engl J Med 350 3 2004 259 265
84. D. Joel The signal attenuation rat model of obsessive-compulsive disorder: a review Psychopharmacology (Berl) 186 4 2006 487 503 (Pubitemid 43855836)
85. P.W. Kalivas The glutamate homeostasis hypothesis of addiction Nat Rev Neurosci 10 8 2009 561 572
86. P. Kamath, Y.C. Reddy, and T. Kandavel Suicidal behavior in obsessive-compulsive disorder J Clin Psychiatry 68 11 2007 1741 1750 (Pubitemid 350247504)
87. H. Katerberg, D.C. Cath, D.A. Denys, P. Heutink, A. Polman, and F.C. van Nieuwerburgh The role of the COMT Val(158)Met polymorphism in the phenotypic expression of obsessive-compulsive disorder Am J Med Genet B Neuropsychiatr Genet 153B 1 2009 167 176
88. H. Kavirajan Memantine: a comprehensive review of safety and efficacy Expert Opin Drug Saf 8 1 2009 89 109
89. D.E. Kemp, W.S. Gilmer, J. Fleck, and P.L. Dago An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder CNS Spectr 12 2 2007 106 111
90. R.C. Kessler, P. Berglund, O. Demler, R. Jin, K.R. Merikangas, and E.E. Walters Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry 62 6 2005 593 602 (Pubitemid 40973434)
91. L.M. Koran, G.L. Hanna, E. Hollander, G. Nestadt, and H.B. Simpson Practice guideline for the treatment of patients with obsessive-compulsive disorder Am J Psychiatry 164 7 Suppl 2007 5 53
92. L.M. Koran, S. Pallanti, and L. Quercioli Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder Eur Neuropsychopharmacol 11 2 2001 169 172 (Pubitemid 32335559)
93. L.M. Koran, M.L. Thienemann, and R. Davenport Quality of life for patients with obsessive-compulsive disorder Am J Psychiatry 153 6 1996 783 788 (Pubitemid 26170539)
94. A.C. Kreitzer Physiology and pharmacology of striatal neurons Annu Rev Neurosci 32 2009 127 147
95. M. Kuloglu, A. Caykoylu, O. Ekinci, and E. Yilmaz Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: a case report J Psychopharmacol 23 8 2009 1001 1003
96. T.C. Kumar, and S. Khanna Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder Aust N Z J Psychiatry 34 3 2000 527 528 (Pubitemid 30389427)
97. M.G. Kushner, S.W. Kim, C. Donahue, P. Thuras, D. Adson, and M. Kotlyar D-cycloserine augmented exposure therapy for obsessive-compulsive disorder Biol Psychiatry 62 8 2007 835 838 (Pubitemid 47488217)
98. J.S. Kwon, Y.H. Joo, H.J. Nam, M. Lim, E.Y. Cho, and M.H. Jung Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms Arch Gen Psychiatry 66 11 2009 1233 1241
99. D.L. Lafleur, C. Pittenger, B. Kelmendi, T. Gardner, S. Wasylink, and R.T. Malison N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder Psychopharmacology (Berl) 184 2 2006 254 256 (Pubitemid 43084809)
100. A. Landeros-Weisenberger, M.H. Bloch, B. Kelmendi, R. Wegner, J. Nudel, and P. Dombrowski Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder J Affect Disord 121 1-2 2010 175 179
101. J.F. Leckman, M.H. Bloch, and R.A. King Symptom dimensions and subtypes of obsessive-compulsive disorder: a developmental perspective Dialogues Clin Neurosci 11 1 2009 21 33
102. J.F. Leckman, W.K. Goodman, W.G. North, P.B. Chappell, L.H. Price, and D.L. Pauls Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder comparison with Tourette's syndrome and healthy controls Arch Gen Psychiatry 51 10 1994 782 792 (Pubitemid 24313304)
103. K.Y. Liang, Y. Wang, Y.Y. Shugart, M. Grados, A.J. Fyer, and S. Rauch Evidence for potential relationship between SLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive-compulsive disorder with compulsive hoarding Am J Med Genet B Neuropsychiatr Genet 147B 6 2008 1000 1002
104. R. Lingamaneni, and H.C. Hemmings Jr. Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes Neurosci Lett 276 2 1999 127 130 (Pubitemid 29525506)
105. A.U. Luescher Diagnosis and management of compulsive disorders in dogs and cats Vet Clin North Am Small Anim Pract 33 2 2003 253 267 vi (Pubitemid 36432121)
106. T.V. Maia, R.E. Cooney, and B.S. Peterson The neural bases of obsessive-compulsive disorder in children and adults Dev Psychopathol 20 4 2008 1251 1283
107. D. Mataix-Cols, M.C. Rosario-Campos, and J.F. Leckman A multidimensional model of obsessive-compulsive disorder Am J Psychiatry 162 2 2005 228 238 (Pubitemid 40216199)
108. D. Mataix-Cols, S. Wooderson, N. Lawrence, M.J. Brammer, A. Speckens, and M.L. Phillips Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder Arch Gen Psychiatry 61 6 2004 564 576 (Pubitemid 38747311)
109. S.J. Mathew, J.M. Amiel, J.D. Coplan, H.A. Fitterling, H.A. Sackeim, and J.M. Gorman Open-label trial of riluzole in generalized anxiety disorder Am J Psychiatry 162 12 2005 2379 2381 (Pubitemid 41740219)
110. C.J. McDougle, C.N. Epperson, G.H. Pelton, S. Wasylink, and L.H. Price A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder Arch Gen Psychiatry 57 8 2000 794 801 (Pubitemid 30650116)
111. C.J. McDougle, W.K. Goodman, J.F. Leckman, N.C. Lee, G.R. Heninger, and L.H. Price Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics Arch Gen Psychiatry 51 4 1994 302 308 (Pubitemid 24127303)
112. M.J. McGrath, K.M. Campbell, C.R. Parks, and F.H. Burton Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder Brain Res 877 1 2000 23 30
113. M.J. McGrath, K.M. Campbell, M.B. Veldman, and F.H. Burton Anxiety in a transgenic mouse model of cortical-limbic neuro-potentiated compulsive behavior Behav Pharmacol 10 5 1999 435 443 (Pubitemid 29440551)
114. L. Menzies, S.R. Chamberlain, A.R. Laird, S.M. Thelen, B.J. Sahakian, and E.T. Bullmore Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited Neurosci Biobehav Rev 32 3 2008 525 549 (Pubitemid 351173336)
115. R.G. Miller, J.D. Mitchell, M. Lyon, and D.H. Moore Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev 1 2007 CD001447
116. B. Moghaddam, and B.W. Adams Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 281 5381 1998 1349 1352 (Pubitemid 28406826)
117. G.J. Moore, F.P. MacMaster, C. Stewart, and D.R. Rosenberg Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder J Am Acad Child Adolesc Psychiatry 37 6 1998 663 667 (Pubitemid 28268228)
118. M.M. Moran, K. McFarland, R.I. Melendez, P.W. Kalivas, and J.K. Seamans Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking J Neurosci 25 27 2005 6389 6393 (Pubitemid 40962534)
119. E.J. Nestler, and S.E. Hyman Animal models of neuropsychiatric disorders Nat Neurosci 13 10 2010 1161 1169
120. A. Nieoullon, B. Canolle, F. Masmejean, B. Guillet, P. Pisano, and S. Lortet The neuronal excitatory amino acid transporter EAAC1/EAAT3: does it represent a major actor at the brain excitatory synapse? J Neurochem 98 4 2006 1007 1018 (Pubitemid 44127778)
121. Y. Nong, Y.Q. Huang, W. Ju, L.V. Kalia, G. Ahmadian, and Y.T. Wang Glycine binding primes NMDA receptor internalization Nature 422 6929 2003 302 307 (Pubitemid 36378356)
122. M.M. Norberg, J.H. Krystal, and D.F. Tolin A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy Biol Psychiatry 63 12 2008 1118 1126
123. E.J. Nordstrom, and F.H. Burton A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry Mol Psychiatry 7 6 2002 617 625 524
124. B.J. O'Roak, T.M. Morgan, D.O. Fishman, E. Saus, P. Alonso, and M. Gratacos Additional support for the association of SLITRK1 var321 and Tourette syndrome Mol Psychiatry 15 5 2010 447 450
125. B.L. Odlaug, and J.E. Grant N-acetyl cysteine in the treatment of grooming disorders J Clin Psychopharmacol 27 2 2007 227 229 (Pubitemid 46594953)
126. J.W. Olney Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate Science 164 880 1969 719 721
127. W.G. Ondo, L. Shinawi, A. Davidson, and D. Lai Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial Parkinsonism Relat Disord 17 3 2011 156 159
128. K.L. Overall, and A.E. Dunham Clinical features and outcome in dogs and cats with obsessive-compulsive disorder: 126 cases (1989-2000) J Am Vet Med Assoc 221 10 2002 1445 1452 (Pubitemid 35340437)
129. C. Ozkara, M. Ozmen, A. Erdogan, and I. Yalug Topiramate related obsessive-compulsive disorder Eur Psychiatry 20 1 2005 78 79 (Pubitemid 40092398)
130. R. Pacheco, T. Gallart, C. Lluis, and R. Franco Role of glutamate on T-cell mediated immunity J Neuroimmunol 185 1-2 2007 9 19 (Pubitemid 46497434)
131. A.S. Parnas, M. Weber, and R. Richardson Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats Neurobiol Learn Mem 83 3 2005 224 231 (Pubitemid 40488810)
132. M. Pasquini, and M. Biondi Memantine augmentation for refractory obsessive-compulsive disorder Prog Neuropsychopharmacol Biol Psychiatry 30 6 2006 1173 1175 (Pubitemid 43928231)
133. D. Perani, V. Garibotto, A. Gorini, R.M. Moresco, M. Henin, and A. Panzacchi In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder Neuroimage 42 1 2008 306 314
134. A. Pinto, B.D. Greenberg, D.L. Murphy, G. Nestadt, and S.A. Rasmussen Using individual items to clarify OCD symptom structure: the case for five factors Am J Psychiatry 166 6 2009 728 729 author reply 729-731
135. C. Pittenger, E. Billingslea, S. Wasylink, M. Bloch, G. Sanacora, and G.F. Mason Reduced anterior cingulate glutamate in obsessive-compulsive disorder: a magnetic resonance spectroscopy study Paper presented at the Society of Biological Psychiatry 2011
136. C. Pittenger, V. Coric, M. Banasr, M. Bloch, J.H. Krystal, and G. Sanacora Riluzole in the treatment of mood and anxiety disorders CNS Drugs 22 9 2008 761 786
137. C. Pittenger, B. Kelmendi, S. Wasylink, M.H. Bloch, and V. Coric Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up J Clin Psychopharmacol 28 3 2008 363 367
138. C. Pittenger, J.H. Krystal, and V. Coric Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder J Clin Psychiatry 66 11 2005 1492 1493 (Pubitemid 41779556)
139. C. Pittenger, J.H. Krystal, and V. Coric Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder NeuroRx 3 1 2006 69 81 (Pubitemid 43276634)
140. C. Pittenger, G. Sanacora, and J.H. Krystal The NMDA receptor as a therapeutic target in major depressive disorder CNS Neurol Disord Drug Targets 6 2 2007 101 115 (Pubitemid 46681771)
141. M. Poyurovsky, I. Glick, and L.M. Koran Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms J Psychopharmacol 24 6 2010 861 866
142. M. Poyurovsky, R. Weizman, A. Weizman, and L. Koran Memantine for treatment-resistant OCD Am J Psychiatry 162 11 2005 2191 2192
143. M. Prakriya, and S. Mennerick Selective depression of low-release probability excitatory synapses by sodium channel blockers Neuron 26 3 2000 671 682
144. R.B. Price, D.C. Shungu, X. Mao, P. Nestadt, C. Kelly, and K.A. Collins Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder Biol Psychiatry 65 9 2009 792 800
145. J. Radua, and D. Mataix-Cols Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder Br J Psychiatry 195 5 2009 393 402
146. J. Radua, O.A. van den Heuvel, S. Surguladze, and D. Mataix-Cols Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other anxiety disorders Arch Gen Psychiatry 67 7 2009 701 711
147. K.J. Ressler, B.O. Rothbaum, L. Tannenbaum, P. Anderson, K. Graap, and E. Zimand Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear Arch Gen Psychiatry 61 11 2004 1136 1144 (Pubitemid 39463415)
148. L.N. Robins, J.E. Helzer, M.M. Weissman, H. Orvaschel, E. Gruenberg, and J.D. Burke Jr. Lifetime prevalence of specific psychiatric disorders in three sites Arch Gen Psychiatry 41 10 1984 949 958 (Pubitemid 14007854)
149. C.I. Rodriguez, L.S. Kegeles, P. Flood, and H.B. Simpson Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder J Clin Psychiatry 72 4 2011 567 569
150. E.T. Rolls, M. Loh, and G. Deco An attractor hypothesis of obsessive-compulsive disorder Eur J Neurosci 28 4 2008 782 793
151. L.M. Rorick-Kehn, B.G. Johnson, K.M. Knitowski, C.R. Salhoff, J.M. Witkin, and K.W. Perry In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders Psychopharmacology (Berl) 193 1 2007 121 136 (Pubitemid 46906627)
152. M.C. Rosario-Campos, J.F. Leckman, M. Curi, S. Quatrano, L. Katsovitch, and E.C. Miguel A family study of early-onset obsessive-compulsive disorder Am J Med Genet B Neuropsychiatr Genet 136B 1 2005 92 97 (Pubitemid 40917536)
153. M.C. Rosario-Campos, J.F. Leckman, M.T. Mercadante, R.G. Shavitt, H.S. Prado, and P. Sada Adults with early-onset obsessive-compulsive disorder Am J Psychiatry 158 11 2001 1899 1903 (Pubitemid 33054785)
154. D.R. Rosenberg, and G.L. Hanna Genetic and imaging strategies in obsessive-compulsive disorder: potential implications for treatment development Biol Psychiatry 48 12 2000 1210 1222 (Pubitemid 32008444)
155. D.R. Rosenberg, F.P. MacMaster, M.S. Keshavan, K.D. Fitzgerald, C.M. Stewart, and G.J. Moore Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine J Am Acad Child Adolesc Psychiatry 39 9 2000 1096 1103
156. D.R. Rosenberg, F.P. Macmaster, Y. Mirza, J.M. Smith, P.C. Easter, and S.P. Banerjee Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study Biol Psychiatry 58 9 2005 700 704 (Pubitemid 41547237)
157. D.R. Rosenberg, S.N. MacMillan, and G.J. Moore Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder Int J Neuropsychopharmacol 4 2 2001 179 190 (Pubitemid 32587386)
158. D.R. Rosenberg, Y. Mirza, A. Russell, J. Tang, J.M. Smith, and S.P. Banerjee Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls J Am Acad Child Adolesc Psychiatry 43 9 2004 1146 1153 (Pubitemid 39096872)
159. J.Y. Rotge, B. Aouizerate, J. Tignol, B. Bioulac, P. Burbaud, and D. Guehl The glutamate-based genetic immune hypothesis in obsessive-compulsive disorder. An integrative approach from genes to symptoms Neuroscience 165 2 2010 408 417
160. J.Y. Rotge, D. Guehl, B. Dilharreguy, E. Cuny, J. Tignol, and B. Bioulac Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies J Psychiatry Neurosci 33 5 2008 405 412
161. B.O. Rothbaum Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder Am J Psychiatry 165 3 2008 293 296 (Pubitemid 351704478)
162. J.D. Rothstein, M. Dykes-Hoberg, C.A. Pardo, L.A. Bristol, L. Jin, and R.W. Kuncl Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate Neuron 16 3 1996 675 686 (Pubitemid 26103145)
163. G. Rubio, M.A. Jimenez-Arriero, I. Martinez-Gras, J. Manzanares, and T. Palomo The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder J Clin Psychopharmacol 26 3 2006 341 344 (Pubitemid 43804634)
164. A.M. Ruscio, D.J. Stein, W.T. Chiu, and R.C. Kessler The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication Mol Psychiatry 15 1 2010 53 63
165. A.S. Sampaio, J. Fagerness, J. Crane, M. Leboyer, R. Delorme, and D.L. Pauls Association between polymorphisms in GRIK2 gene and obsessive-compulsive disorder: a family-based study CNS Neurosci Ther 17 2011 141 147
166. J. Samuels, Y. Wang, M.A. Riddle, B.D. Greenberg, A.J. Fyer, and J.T. McCracken Comprehensive family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder Am J Med Genet B Neuropsychiatr Genet 156 4 2011 472 477
167. G. Sanacora, R. Gueorguieva, C.N. Epperson, Y.T. Wu, M. Appel, and D.L. Rothman Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression Arch Gen Psychiatry 61 7 2004 705 713 (Pubitemid 38890805)
168. G. Sanacora, S.F. Kendell, L. Fenton, V. Coric, and J.H. Krystal Riluzole augmentation for treatment-resistant depression Am J Psychiatry 161 11 2004 2132
169. G. Sanacora, S.F. Kendell, Y. Levin, A.A. Simen, L.R. Fenton, and V. Coric Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms Biol Psychiatry 61 6 2007 822 825 (Pubitemid 46330247)
170. R.A. Sansone, and L.A. Sansone Getting a knack for NAC: N-acetyl-cysteine Innov Clin Neurosci 8 1 2011 10 14
171. D.A. Sasso, P.S. Kalanithi, K.V. Trueblood, C. Pittenger, B. Kelmendi, and S. Wayslink Beneficial effects of the glutamate-modulating agent riluzole on disordered eating and pathological skin-picking behaviors J Clin Psychopharmacol 26 6 2006 685 687 (Pubitemid 44772760)
172. A.P. Schmidt, A.B. Tort, P.P. Silveira, A.E. Bohmer, G. Hansel, and L. Knorr The NMDA antagonist MK-801 induces hyperalgesia and increases CSF excitatory amino acids in rats: reversal by guanosine Pharmacol Biochem Behav 91 4 2009 549 553
173. K. Seksel, and M.J. Lindeman Use of clomipramine in treatment of obsessive-compulsive disorder, separation anxiety and noise phobia in dogs: a preliminary, clinical study Aust Vet J 79 4 2001 252 256 (Pubitemid 33644856)
174. N.A. Shanahan, K.A. Holick Pierz, V.L. Masten, C. Waeber, M. Ansorge, and J.A. Gingrich Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice Biol Psychiatry 65 5 2009 401 408
175. G.M. Shepherd The Synaptic Organization of the Brain 5th ed. 2004 Oxford University Press New York
176. S.V. Shmelkov, A. Hormigo, D. Jing, C.C. Proenca, K.G. Bath, and T. Milde Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice Nat Med 16 5 2010 598 602 591p following 602
177. Y.Y. Shugart, Y. Wang, J.F. Samuels, M.A. Grados, B.D. Greenberg, and J.A. Knowles A family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder in 378 families Am J Med Genet B Neuropsychiatr Genet 150B 6 2009 886 892
178. S.H. Snyder, and C.D. Ferris Novel neurotransmitters and their neuropsychiatric relevance Am J Psychiatry 157 11 2000 1738 1751
179. G.M. Soomro, D. Altman, S. Rajagopal, and M. Oakley-Browne Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) Cochrane Database Syst Rev 1 2008 CD001765
180. G. Starck, M. Ljungberg, M. Nilsson, L. Jonsson, S. Lundberg, and T. Ivarsson A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity J Neural Transm 115 7 2008 1051 1062
181. S.E. Stewart, J.A. Fagerness, J. Platko, J.W. Smoller, J.M. Scharf, and C. Illmann Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder Am J Med Genet B Neuropsychiatr Genet 144B 8 2007 1027 1033 (Pubitemid 350207777)
182. S.E. Stewart, E.A. Jenike, D.M. Hezel, D.E. Stack, N.H. Dodman, and L. Shuster A single-blinded case-control study of memantine in severe obsessive-compulsive disorder J Clin Psychopharmacol 30 1 2010 34 39
183. E.A. Storch, L.J. Merlo, M. Bengtson, T.K. Murphy, M.H. Lewis, and M.C. Yang D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder Int Clin Psychopharmacol 22 4 2007 230 237 (Pubitemid 46801947)
184. E.A. Storch, T.K. Murphy, W.K. Goodman, G.R. Geffken, A.B. Lewin, and A. Henin A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder Biol Psychiatry 68 11 2010 1073 1076
185. E.A. Storch, T.K. Murphy, W.K. Goodman, G.R. Geffken, A.B. Lewin, and A. Henin A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder Biol Psychiatry 68 11 2010 1073 1076
186. S. Sumitani, M. Harada, H. Kubo, and T. Ohmori Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients Psychiatry Res 154 1 2007 85 92 (Pubitemid 46072703)
187. S.E. Swedo, and P.J. Grant Annotation: PANDAS: a model for human autoimmune disease J Child Psychol Psychiatry 46 3 2005 227 234 (Pubitemid 40439428)
188. S.E. Swedo, H.L. Leonard, and J.L. Rapoport The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction Pediatrics 113 4 2004 907 911 (Pubitemid 38437398)
189. S.E. Swedo, A. Schrag, R. Gilbert, G. Giovannoni, M.M. Robertson, and C. Metcalfe Streptococcal infection, Tourette syndrome, and OCD: is there a connection? PANDAS: horse or zebra Neurology 74 17 2010 1397 1398 author reply 1398-1399
190. H. Szechtman, W. Sulis, and D. Eilam Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD) Behav Neurosci 112 6 1998 1475 1485 (Pubitemid 29052635)
191. H. Szechtman, and E. Woody Obsessive-compulsive disorder as a disturbance of security motivation Psychol Rev 111 1 2004 111 127 (Pubitemid 38157078)
192. K. Tanaka, K. Watase, T. Manabe, K. Yamada, M. Watanabe, and K. Takahashi Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1 Science 276 5319 1997 1699 1702 (Pubitemid 27421977)
193. Y.P. Tang, E. Shimizu, G.R. Dube, C. Rampon, G.A. Kerchner, and M. Zhuo Genetic enhancement of learning and memory in mice Nature 401 6748 1999 63 69
194. A. Thomas, A. Burant, N. Bui, D. Graham, L.A. Yuva-Paylor, and R. Paylor Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety Psychopharmacology (Berl) 204 2 2009 361 373
195. J. Thuile, C. Even, and J.D. Guelfi Topiramate may induce obsessive-compulsive disorder Psychiatry Clin Neurosci 60 3 2006 394 (Pubitemid 43736408)
196. J.T. Ting, and G. Feng Glutamatergic synaptic dysfunction and obsessive-compulsive disorder Curr Chem Genomics 2 2008 62 75
197. E. Tsaltas, D. Kontis, S. Chrysikakou, H. Giannou, A. Biba, and S. Pallidi Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology Biol Psychiatry 57 10 2005 1176 1185 (Pubitemid 40615780)
198. F. Uguz, C. Akman, N. Kaya, and A.S. Cilli Postpartum-onset obsessive-compulsive disorder: incidence, clinical features, and related factors J Clin Psychiatry 68 1 2007 132 138 (Pubitemid 46220135)
199. O. Uzun Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report J Psychopharmacol 24 3 2010 425 427
200. M. Van Ameringen, C. Mancini, B. Patterson, and M. Bennett Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series Depress Anxiety 23 1 2006 1 5
201. O.A. van den Heuvel, P.L. Remijnse, D. Mataix-Cols, H. Vrenken, H.J. Groenewegen, and H.B. Uylings The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems Brain 132 Pt 4 2009 853 868
202. D.J. Vinkers, and N.J. van der Wee Topiramate augmentation in treatment-resistant obsessive-compulsive disorder Tijdschr Psychiatr 50 11 2008 747 750
203. R. Wald, N. Dodman, and L. Shuster The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder Exp Clin Psychopharmacol 17 3 2009 191 197
204. D.L. Walker, K.J. Ressler, K.T. Lu, and M. Davis Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of d-cycloserine as assessed with fear-potentiated startle in rats J Neurosci 22 6 2002 2343 2351 (Pubitemid 35386533)
205. Y. Wang, A. Adamczyk, Y.Y. Shugart, J.F. Samuels, M.A. Grados, and B.D. Greenberg A screen of SLC1A1 for OCD-related alleles Am J Med Genet B Neuropsychiatr Genet 153B 2 2010 675 679
206. J.M. Welch, J. Lu, R.M. Rodriguiz, N.C. Trotta, J. Peca, and J.D. Ding Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice Nature 448 7156 2007 894 900 (Pubitemid 47312780)
207. J.M. Welch, D. Wang, and G. Feng Differential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse J Comp Neurol 472 1 2004 24 39 (Pubitemid 38393305)
208. J.R. Wendland, P.R. Moya, K.R. Timpano, A.P. Anavitarte, M.R. Kruse, and M.G. Wheaton A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder Arch Gen Psychiatry 66 4 2009 408 416
209. S.P. Whiteside, J.D. Port, B.J. Deacon, and J.S. Abramowitz A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety Psychiatry Res 146 2 2006 137 147
210. S. Wilhelm, U. Buhlmann, D.F. Tolin, S.A. Meunier, G.D. Pearlson, and H.E. Reese Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder Am J Psychiatry 165 3 2008 335 341 quiz 409 (Pubitemid 351704489)
211. V.L. Willour, Y. Yao Shugart, J. Samuels, M. Grados, B. Cullen, and O.J. Bienvenu III Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder Am J Hum Genet 75 3 2004 508 513 (Pubitemid 39095826)
212. P.L. Wu, H.S. Tang, H.Y. Lane, C.A. Tsai, and G.E. Tsai Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study J Clin Psychopharmacol 31 3 2011 369 374
213. D. Wynchank, and M. Berk Fluoxetine treatment of acral lick dermatitis in dogs: a placebo-controlled randomized double blind trial Depress Anxiety 8 1 1998 21 23 (Pubitemid 28413061)
214. J.A. Yaryura-Tobias, F. Neziroglu, and H.N. Bhagavan Obsessive-compulsive disorders: a serotonergic hypothesis B. Saletu, P. Berner, L. Hollister, Neuropsychopharmacology: Proceedings of the 11th Congress of the CNIP 1979 Pergamon Oxford, UK 117 125
215. M. Yucel, S.J. Wood, R.M. Wellard, B.J. Harrison, A. Fornito, and J. Pujol Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder Aust N Z J Psychiatry 42 6 2008 467 477 (Pubitemid 351891125)
216. C. Yuksel, and D. Ongur Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders Biol Psychiatry 68 9 2010 785 794
217. C.A. Zarate Jr., J.L. Payne, J. Quiroz, J. Sporn, K.K. Denicoff, and D. Luckenbaugh An open-label trial of riluzole in patients with treatment-resistant major depression Am J Psychiatry 161 1 2004 171 174 (Pubitemid 38419327)
218. C.A. Zarate Jr., J.A. Quiroz, J.B. Singh, K.D. Denicoff, G. De Jesus, and D.A. Luckenbaugh An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression Biol Psychiatry 57 4 2005 430 432 (Pubitemid 40215774)
219. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 8 2006 856 864 (Pubitemid 44188478)
220. C.A. Zarate Jr., J.B. Singh, J.A. Quiroz, G. De Jesus, K.K. Denicoff, and D.A. Luckenbaugh A double-blind, placebo-controlled study of memantine in the treatment of major depression Am J Psychiatry 163 1 2006 153 155 (Pubitemid 43050119)
221. C.A. Zarate, and H.K. Manji Riluzole in psychiatry: a systematic review of the literature Expert Opin Drug Metab Toxicol 4 9 2008 1223 1234
222. J. Zohar, J.L. Kennedy, E. Hollander, and L.M. Koran Serotonin-1D hypothesis of obsessive-compulsive disorder: an update J Clin Psychiatry 65 Suppl 14 2004 18 21
223. Zuchner, S., Wendland, J. R., Ashley-Koch, A. E., Collins, A. L., Tran-Viet, K. N., Quinn, K., et al. (2009). Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol Psychiatry 14(1), 6-9.